HC Wainwright Has Pessimistic Outlook of TRAX Q2 Earnings

First Tracks Biotherapeutics (NASDAQ:TRAX) – Equities researchers at HC Wainwright dropped their Q2 2026 EPS estimates for First Tracks Biotherapeutics in a research note issued on Wednesday, July 8th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.90) per share for the quarter, down from their previous estimate of ($0.86). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock.

TRAX has been the topic of several other reports. UBS Group started coverage on First Tracks Biotherapeutics in a report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 target price for the company. Wedbush started coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $30.00 price target on the stock. Leerink Partners initiated coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $46.00 price objective for the company. Piper Sandler initiated coverage on shares of First Tracks Biotherapeutics in a research report on Monday, May 4th. They set an “overweight” rating and a $54.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.25.

First Tracks Biotherapeutics Stock Performance

Shares of NASDAQ TRAX opened at $32.40 on Friday. First Tracks Biotherapeutics has a twelve month low of $14.72 and a twelve month high of $33.70. The stock has a market cap of $1.13 billion and a price-to-earnings ratio of -17.61. The stock has a 50 day moving average price of $18.20.